Key Highlights
- $145 million Series E funding led by Nextech Invest, with contributions from top investors including RA Capital and General Catalyst.
- Funding to accelerate clinical development of FOG-001, targeting the Wnt/β-catenin signaling pathway in solid tumors.
- Helicon™ peptide platform combines advanced peptides with AI for unprecedented drug discovery and development capabilities.
Source: Business Wire
Notable Quotes
- “Millions of colorectal cancer patients have been told by their oncologists that no more can be done for them. We believe FOG-001 may represent the long-awaited major technological breakthrough needed to address one of the most common yet unaddressed oncogenic signaling pathways,” – Mathai Mammen, M.D., Ph.D., Chairman, President, and CEO at FogPharma
- “We are excited by the tremendous potential of FOG-001 to meaningfully change the therapeutic landscape through a novel approach,” – Thilo Schroeder, Ph.D., Managing Partner at Nextech
SoHC's Take
The announcement by FogPharma of a successful $145 million Series E financing round marks a pivotal moment in the fight against cancer, especially colorectal cancer. The funds will propel the development of FOG-001, aiming at a long-unaddressed target in cancer treatment. This development underscores a significant advancement in biopharmaceutical innovation, leveraging the Helicon™ peptide platform to overcome historical drug delivery challenges within cells. The commitment from both new and existing investors illustrates a robust confidence in FogPharma’s approach and its potential to transform cancer therapy. With a strong leadership team and cutting-edge technology, FogPharma is well-positioned to lead the charge in unlocking new therapeutic avenues for patients worldwide.
